Earth Science Tech, Inc. (ETST) and Dermagate: A New Partnership in the Advancement of Women’s Health
- Partnering with Dermagate to improve the health of women worldwide
- Working toward qualification of an accreditation that will open more doors worldwide
- A promising year lays ahead with access to additional medical devices for ETST and an accelerated-to-market certification process for Hygee
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company developing and marketing health-oriented products, has partnered with Dermagate, a fast growing company specializing in the manufacturing of dermatology and wound care products, to manufacture Hygee medical devices. A recent press release (http://nnw.fm/g27ZN) emphasizes that both companies share a concern for the health of women worldwide, making them a natural fit in the production and distribution of this self-sampling kit that allows women to test for sexually transmitted infections (STIs) in the privacy of their own homes.
Hygee has already been proven successful in detecting chlamydia. Testing for additional STIs and non-STI infections will be added soon. The goal of the current medical device is to help reduce the overall spread of chlamydia and help women avoid the dangerous complications of this STI. By providing an affordable, discreet testing procedure, ETST is empowering woman to take charge of their health. Dermagate is making it possible to produce and distribute these kits worldwide.
Dermagate holds the necessary ISO 13485:2013 certifications that will allow for distribution and has already begun the application process for the new Medical Device Single Audit Program (MDSAP) certification of all of its products, including Hygee. The MDSAP will soon replace the ISO 13485:2013 certification. Australia, Brazil, Canada, Japan and the United States are five major markets that will soon adopt the new certification. The advantage of MDSAP, which is also being considered by additional countries, is that one accreditation covers all participating countries rather than having to earn a new accreditation for every individual country.
Next year promises to be a productive one for ETST, as this new partnership will give the company access to additional medical devices for distribution. Certification for the distribution of Hygee in Canada is expected to take place in January. Certification for distribution in various other countries is anticipated in mid-2019. In addition to Hygee, two new nutraceutical products are scheduled to be launched in the coming year.
“The volume of first-year sales for Hygee will probably be far more than anticipated,” Gaétan Houle, president and CEO of PharmaGate Group Inc. and Dermagate, stated in a news release. “We are not afraid of success. We are able to scale the production to any level needed to meet the worldwide market needs.”
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Partnering with Dermagate to improve the health of women worldwide
- Working toward qualification of an accreditation that will open more doors worldwide
- A promising year lays ahead with access to additional medical devices for ETST and an accelerated-to-market certification process for Hygee
Earth Science Tech, Inc. (OTCQB: ETST), a biotech company developing and marketing health-oriented products, has partnered with Dermagate, a fast growing company specializing in the manufacturing of dermatology and wound care products, to manufacture Hygee medical devices. A recent press release (http://nnw.fm/g27ZN) emphasizes that both companies share a concern for the health of women worldwide, making them a natural fit in the production and distribution of this self-sampling kit that allows women to test for sexually transmitted infections (STIs) in the privacy of their own homes.
Hygee has already been proven successful in detecting chlamydia. Testing for additional STIs and non-STI infections will be added soon. The goal of the current medical device is to help reduce the overall spread of chlamydia and help women avoid the dangerous complications of this STI. By providing an affordable, discreet testing procedure, ETST is empowering woman to take charge of their health. Dermagate is making it possible to produce and distribute these kits worldwide.
Dermagate holds the necessary ISO 13485:2013 certifications that will allow for distribution and has already begun the application process for the new Medical Device Single Audit Program (MDSAP) certification of all of its products, including Hygee. The MDSAP will soon replace the ISO 13485:2013 certification. Australia, Brazil, Canada, Japan and the United States are five major markets that will soon adopt the new certification. The advantage of MDSAP, which is also being considered by additional countries, is that one accreditation covers all participating countries rather than having to earn a new accreditation for every individual country.
Next year promises to be a productive one for ETST, as this new partnership will give the company access to additional medical devices for distribution. Certification for the distribution of Hygee in Canada is expected to take place in January. Certification for distribution in various other countries is anticipated in mid-2019. In addition to Hygee, two new nutraceutical products are scheduled to be launched in the coming year.
“The volume of first-year sales for Hygee will probably be far more than anticipated,” Gaétan Houle, president and CEO of PharmaGate Group Inc. and Dermagate, stated in a news release. “We are not afraid of success. We are able to scale the production to any level needed to meet the worldwide market needs.”
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
